Global Community

Champion Breweries has delivered a strong recovery in H1 2025 , recording a notable swing from prior-year losses to a solid profit. The company posted: Revenue growth of 67% YoY to ₦15.93bn Gross profit more than doubled to ₦7.89bn (from ₦3.73bn) Profit after tax of ₦2.29bn compared to a loss of ₦387m in H1 2024 Basic EPS improved to 25.57 kobo , from a loss per share of 4.94 kobo ✅ Strengths: Significant revenue growth (both quarterly and year-to-date), indicating increased market penetration or pricing power.

Summary: BUA Cement delivered a stellar financial performance in H1 2025, with revenue rising 59.4% YoY to ₦580.3 billion and PAT surging over 428% YoY to ₦180.9 billion. This growth reflects pricing power, improved volume uptake, and operational efficiency.

Q2/H1 Result Solid Growth Trajectory with Strong Margins but Funding Cost Pressures Remain Infinity Trust Mortgage Bank Plc (ITMB) has delivered strong double-digit growth in both top-line and bottom-line metrics in H1 2025, reflecting the strength of its mortgage-focused business model amid Nigeria’s rising demand for housing finance. The bank’s ability to sustain profitability while aggressively expanding its loan book and asset base positions it as a viable growth stock in the financial services sector.

Overview: Africa Prudential delivered a strong first-half performance in 2025, growing profit after tax by 72.6% YoY to ₦1.35 billion, largely on the back of a surge in interest income and improved revenue from contracts with customers. However, rising operating expenses, significant drawdown in cash position, and elevated customer deposit liabilities present risks to liquidity and capital efficiency.

Based on the projections presented by the company on the investor day of March 31, 2025, we will assume 5-year fundamental projection for BlackRock based on its 2024 results and strategic targets: Assumptions Revenue CAGR : 10% annually, aligned with BlackRock’s 2030 ambition. Operating Margin : Maintained at 45% (as adjusted).

Pipeline Crenessity@ CRENESSITY Capsule 50/100 MG $766.66 packaging 50 MG 60u $45,999.60 packaging 100 MG 30u. Starts at approximately $21,338.71 USD for a monthly supply Ingrezza@ Ingrezza (valbenazine) As of July 2025 , the average pharmacy acquisition cost for Ingrezza capsules in the U.S. is approximately: $274.54 per capsule for the 60 mg and 80 mg strengths $250.16 per capsule for the 40 mg strength Other Products: Tetrabenazine Tablet 12.5 MG $62.52 Austedo Tablet 6 MG $100.06 Austedo XR Tablet 6 MG $100.06 Xenazine Tablet 12.5 MG $227.88 Assumptions Risks Risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, risks and uncertainties associated with the commercialization of INGREZZA and CRENESSITY.

Recent Financial Performance In H1 2025, Rovi’s net profit dropped by 10% to €39.7 million. The decline was mainly due to reduced third-party manufacturing, especially COVID-19 vaccine production.

Guinness Nigeria Plc has delivered a dramatic financial turnaround in FY 2025, posting ₦16.2bn in profit after tax , compared to a ₦54.7bn loss in FY 2024. The company’s strategic realignment and disciplined cost control have restored profitability and market confidence.

Transcorp Hotels Plc continues to deliver robust growth in revenue and profit , bolstered by operating leverage, efficient cost control, and a strong balance sheet. The company recorded a 60% YoY revenue increase in H1 2025 and a 31% surge in net profit , underpinned by post-pandemic demand resurgence, effective expense management, and low gearing.